Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mymetics Corp (MYMX)

Mymetics Corp (MYMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant

- Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. - Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern...

MYMX : 0.0100 (-96.16%)
Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine

- Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based...

MYMX : 0.0100 (-96.16%)
Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine

- Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective...

MYMX : 0.0100 (-96.16%)
Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)

EPALINGES, SWITZERLAND / ACCESSWIRE / June 11, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life...

MYMX : 0.0100 (-96.16%)
Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy

EPALINGES, SWITZERLAND / ACCESSWIRE / May 28, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life...

MYMX : 0.0100 (-96.16%)
Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines

EPALINGES, SWITZERLAND / ACCESSWIRE / May 18, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life...

MYMX : 0.0100 (-96.16%)

Barchart Exclusives

Apple Stock Surges on Buyback and Dividend News - OTM Options are Cheap Here
Apple stock is up on its massive buyback news - a new $110 billion program, as well as a 4% dividend hike. These work out to 4.39% of its market cap. Today AAPL OTM put and call options are cheap - good for long-term investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar